CPRPLOT2: Stata module to graph component-plus-residual plots for transformed regressors

cprplot2 is a variation of official Stata's cprplot and is used for graphing component-plus-residual plots (a.k.a. partial residual plots). Additional features (compared to cprplot): (1) cprplot2 can handle variables that enter the model repeatedly via different transformations (for example, polynomials). (2) cprplot2 can display component-plus-residual plots using the original units for transformed variables in the model. (3) A wrapper is provided to quickly display several component-plus-residual plots in a single image.

Laboratory investigation of residual liquid organics from spills, leaks, and the disposal of hazardous wastes in groundwater /

Mode of access: Internet.

Comparison of methods for the determination of total available residual chlorine in various sample matrices /

Bibliography: p. 28-29.

A study of the residual ionization in a gas with reference to temperature effects ...

"Reprinted from the Physical review, n. s., vol. XVI, no. 4, October, 1920."

Methods to reduce built-in residual stresses in steel bridge diaphragms (Phase I) /

"July 2000."

Fomes annosus in the southeastern United States : relation of environmental and biotic factors to stump colonization and losses in the residual stand /

Literature cited: p. 24-26.

Residual effects of fall- and spring-applied nitrogen fertilizers on crop yields in the southeastern United States /

Caption title.

Residual stress and the yield strength of steel beams,

Sponsored jointly by the Welding Research Council and the Department of the Navy.

The psychotogenic effects of cannabis use: challenges in reducing residual uncertainties and communicating the risks

No Abstract

Pathological complete response and residual DCIS following neoadjuvant chemotherapy for breast carcinoma

Patients who have no residual invasive cancer following neoadjuvant chemotherapy for breast carcinoma have a better overall survival than those with residual disease. Many classification systems assessing pathological response to neoadjuvant chemotherapy include residual ductal carcinoma in situ (DCIS) only in the definition of pathological complete response. The purpose of this study was to investigate whether patients with residual DCIS only have the same prognosis as those with no residual invasive or in situ disease. A retrospective analysis of a prospectively maintained database identified 435 patients, who received neoadjuvant chemotherapy for operable breast cancer between February 1985 and February 2003. Of these, 30 (7%; 95% CI 5-9%) had no residual invasive disease or DCIS and 20 (5%; CI 3-7%) had residual DCIS only. With a median follow-up of 61 months, there was no statistical difference in disease-free survival, 80% (95% CI 60-90%) in those with no residual invasive or in situ disease and 61% (95% CI 35-80%) in those with DCIS only (P = 0.4). No significant difference in 5-year overall survival was observed, 93% (95% CI 75-98%) in those with no residual invasive or in situ disease and 82% (95% CI 52-94%) in those with DCIS only (P = 0.3). Due to the small number of patients and limited number of events in each group, it is not possible to draw definitive conclusions from this study. Further analyses of other databases are required to confirm our finding of no difference in disease-free and overall survival between patients with residual DCIS and those with no invasive or in situ disease following neoadjuvant chemotherapy for breast cancer.